Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00651352 | A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges | PHASE1 | COMPLETED | 32 | — | — | Feb 1, 2008 | Mar 1, 2008 | Nov 24, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| 2 mg nicotine prototype | EXPERIMENTAL | 2 mg nicotine prototype |
| 2 mg nicotine lozenge | ACTIVE_COMPARATOR | marketed formulation |
| 4 mg nicotine prototype | EXPERIMENTAL | 4 mg |
| 4 mg nicotine lozenge | ACTIVE_COMPARATOR | 4 mg |
| Name | Type | Description |
|---|---|---|
| 4 mg nicotine lozenge | DRUG | marketed formulation |
| 2 mg nicotine lozenge | DRUG | marketed formulation |
| 2 mg nicotine prototype | DRUG | 2 mg |
| 4 mg nicotine prototype | DRUG | 4 mg |
Inclusion Criteria: * Subject is either male or female between 18 - 55 years of age inclusive. * Subject has a BMI within the range 19-27 kg/m². \[BMI = Weight (kg) ÷ Height (m)²\]. * Subject admits to having smoked commercially-available cigarettes daily for the preceding 12 months and to routinel...